Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bristol Myers Squibb
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
January 28, 2022
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
January 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
IPSC
Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference
January 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
January 04, 2022
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022
December 17, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
December 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
December 14, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
IMTX
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
December 13, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results
December 11, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
December 03, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
November 29, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
November 23, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
November 19, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
November 18, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
November 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease
November 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference
November 10, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
November 08, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
November 08, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
November 04, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases
November 03, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
October 27, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)
October 25, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …
October 21, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained
October 20, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
October 15, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Up to Five Years of Data from Long-Term DAYBREAK Study Reinforcing Efficacy and Safety Profile of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
October 13, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients With Moderate to Severe Ulcerative Colitis
October 07, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Hold Investor Event on November 16
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
European Medicines Agency Validates Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as First-Line Treatment for Patients with Unresectable or Metastatic Melanoma
October 01, 2021
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.